𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Utilization of oncoprotein-pulsed dendritic cells as tumor vaccines

✍ Scribed by Jan Bubeník

Book ID
106124599
Publisher
Springer-Verlag
Year
2001
Tongue
English
Weight
67 KB
Volume
127
Category
Article
ISSN
1432-1335

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Toll-like receptor agonists as third sig
Toll-like receptor agonists as third signals for dendritic cell–tumor fusion vaccines
✍ Edward I. Cho; Chunrui Tan; Gary K. Koski; Peter A. Cohen; Suyu Shu; Walter T. L 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 214 KB

## Abstract ## Background The aim of the present study was to evaluate the therapeutic efficacy of dendritic cell (DC)–tumor fusion hybrids with Toll‐like receptor (TLR) agonists. ## Methods DC–tumor fusion hybrids were generated by electrofusion and injected into the inguinal lymph nodes of C57

Intrahepatic delivery of α-galactosylcer
Intrahepatic delivery of α-galactosylceramide-pulsed dendritic cells suppresses liver tumor
✍ Tomohide Tatsumi; Tetsuo Takehara; Shinjiro Yamaguchi; Akira Sasakawa; Ryotaro S 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 386 KB

## Alpha -galactosylceramide, a glycosphingolipid, mediates interaction of dendritic cells (DCs) and NKT cells, leading to activation of both innate and acquired immunity. For cancer treatment, conventional DC-based vaccine has been tried, but its clinical efficacy is limited against liver cancer.